Coegin Pharma AB reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative revenue was SEK 0.139 million compared to revenue of SEK 0.345 million a year ago. Net loss was SEK 8.52 million compared to SEK 2.5 million a year ago. Basic loss per share from continuing operations was SEK 0.012 compared to SEK 0.004 a year ago. Diluted loss per share from continuing operations was SEK 0.012 compared to SEK 0.004 a year ago.
For the nine months, revenue was SEK 2.68 million compared to SEK 0.799 million a year ago. Net loss was SEK 27.81 million compared to SEK 19.36 million a year ago. Basic loss per share from continuing operations was SEK 0.04 compared to SEK 0.032 a year ago. Diluted loss per share from continuing operations was SEK 0.04 compared to SEK 0.032 a year ago.